Saverna Therapeutics to date has been financed through a mixture of self-funding, grant awards from Switzerland and Europe via Innosuisse and Eurostars programs.
All in all a total of approximately CHF 2 mio non-dilutive cash and cash-in-kind has been invested in the company (founders and angel investors funds). The value created to date is CHF 3.5 mio. The Company is now seeking to conclude a seed investment round of CHF 3-4 mio. in one-to-three tranches to cover the period 2019/2020-2022 to advance its SLE project and to develop drugs for inflammation, autoimmune and infectious diseases and cancer.
Would you like to find out more about investment opportunities with Saverna Therapeutics or would you like to be a part of our journey on creating new innovative solutions for the world?
Get in touch with us.